Trials / Completed
CompletedNCT01134367
An Epidemiological Study to Describe Symptom Control and Impact of Gastroesophageal Reflux Disease
An Epidemiological, Postmarketing Observational Study to Describe Symptom Control and Impact of Gastroesophageal Reflux Disease (GERD) on Patients' Daily Life
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,000 (estimated)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to examine patient's perspective of symptom control and impact of gastroesophageal reflux disease (GERD) on daily life.
Conditions
Timeline
- Start date
- 2010-05-01
- Primary completion
- 2010-12-01
- Completion
- 2010-12-01
- First posted
- 2010-06-02
- Last updated
- 2011-07-14
Locations
7 sites across 1 country: Serbia
Source: ClinicalTrials.gov record NCT01134367. Inclusion in this directory is not an endorsement.